Complement Inhibition in ANCA-Associated Vasculitis [PDF]
Frontiers in Immunology, 2022 Efficacy of immunosuppressive treatment of Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is complicated by its toxicity. With the replacement of cyclophosphamide with rituximab, serious adverse events seem to be associated ...
Vladimir Tesar, Zdenka Hruskova
doaj +4 more sources
Targeted complement inhibition using bispecific antibodies that bind local antigens and endogenous complement regulators [PDF]
Frontiers in ImmunologyComplement activation protects against infection but also contributes to pathological mechanisms in a range of clinical conditions such as autoimmune diseases and transplant rejection.
Haiyu Wang +18 more
doaj +4 more sources
Complement inhibition rapidly blocks lesion extension and facilitates remyelination in neuromyelitis optica [PDF]
Acta Neuropathologica CommunicationsCumulative disability in neuromyelitis optica spectrum disorder (NMOSD) results from incomplete recovery following inflammatory, demyelinating attacks.
Katherine S Given +5 more
doaj +3 more sources
24 The role of complement and complement inhibition in APS pregnancy [PDF]
Lupus Science and Medicine, 2021 Women with antiphospholipid syndrome (APS) are at increased risk for adverse pregnancy outcomes, including preeclampsia, fetal and neonatal death and fetal growth restriction. Studies in mice implicate inflammation, particularly complement activation, as an essential and causative factor in placental insufficiency, fetal loss and growth restriction.1 ...
Jane Salmon
doaj +2 more sources
Advancements in complement inhibition for PNH and primary complement–mediated thrombotic microangiopathy [PDF]
Blood Advances: Paroxysmal nocturnal hemoglobinuria (PNH) and primary complement–mediated thrombotic microangiopathy, also known as atypical hemolytic uremic syndrome (aHUS), are hematologic disorders characterized by dysregulation of the complement system leading to ...
Thalia Padilla Kelley +5 more
doaj +2 more sources
Pegcetacoplan: A New Opportunity for Complement Inhibition in PNH [PDF]
Journal of Blood Medicine, 2023 Ilene Ceil Weitz Jane Anne Nohl Division of Hematology, Keck-USC School of Medicine, Los Angeles, CA, USACorrespondence: Ilene Ceil Weitz, Jane Anne Nohl Division of Hematology, Keck-USC School of Medicine, Los Angeles, CA, USA, Tel +1-323-865-3950, Fax +
Weitz IC
doaj +2 more sources
Complement Activation and Inhibition in Wound Healing [PDF]
Clinical and Developmental Immunology, 2012 Complement activation is needed to restore tissue injury; however, inappropriate activation of complement, as seen in chronic wounds can cause cell death and enhance inflammation, thus contributing to further injury and impaired wound healing. Therefore,
Gwendolyn Cazander +2 more
doaj +7 more sources
Effects of complement inhibition on the ABC phenomenon in rats
Asian Journal of Pharmaceutical Sciences, 2017 Researchers reported that intravenously injected PEGylated colloidal drug carriers lose their long-circulating characteristic and accumulated extensively in liver when they are administrated twice in the same animal with certain intervals.
Lirong Wang +8 more
doaj +3 more sources
Terminal complement inhibition in atypical haemolytic uremic syndrome: a single-centre experience [PDF]
Frontiers in PharmacologyBackgroundAtypical hemolytic uremic syndrome (aHUS) is a rare thrombotic microangiopathy (TMA) caused by complement dysregulation, leading to microangiopathic anemia, thrombocytopenia, and acute kidney injury (AKI).
Valentin D. Mocanu +17 more
doaj +2 more sources
Features of Postpartum Hemorrhage-Associated Thrombotic Microangiopathy and Role of Short-Term Complement Inhibition [PDF]
Kidney International ReportsIntroduction: In pregnancy-related atypical hemolytic uremic syndrome (p-aHUS), transferring recommendations for treatment decisions from nonpregnant cohorts with thrombotic microangiopathy (TMA) is difficult.
Jessica K. Kaufeld +11 more
doaj +2 more sources